Nasdaq GlobeNewswire

Merus Announces Annual Meeting of Shareholders

Del

UTRECHT, The Netherlands, July 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20, 2018 at 8:00 a.m. CEST, at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands).

All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus' website (www.merus.nl) under "Financial Information".

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Additional pipeline programs include MCLA-117, which is currently being studied in a Phase 1 clinical trial in patients with acute myeloid leukemia, and MCLA-158, a Biclonics® being studied in a Phase 1 clinical trial in patients with solid tumors with an initial focus on metastatic colorectal cancer. Through its collaboration with Incyte Corporation, Merus is also developing a preclinical bispecific antibody designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. For additional information, please visit Merus' website, www.merus.nl.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the treatment potential, progress, timing and plans for the clinical development of our candidates, including MCLA-117, MCLA-128, and MCLA-158.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics® and bispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaboration with Incyte or Incyte may fail to perform adequately under our collaboration; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in existing and potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.

These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on April 30, 2018, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts:

Investors:

Kimberly Minarovich

+1 646-368-8014

kimberly@argotpartners.com  

Media:

David Rosen

+1 212-600-1902

david.rosen@argotpartners.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Wencor Group Announces Acquisition of Silver Wings14.11.2018 15:58Pressemelding

Peachtree City, GA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- WENCOR GROUP ANNOUNCES ACQUISITION OF SILVER WINGS Peachtree City, GA (November 8th, 2018) -- Wencor Group (“Wencor”), a leading solutions provider to the aerospace aftermarket, today announced the acquisition of Silver Wings Aerospace, a certified 145 repair station specializing in electric power and hydraulic component repair with unique capabilities in Used Serviceable Material (“USM”). Terms of the transaction were not disclosed. "We are pleased to welcome Silver Wings leadership and their employees to the Wencor team. This partnership aligns with our strategy to drive ATA chapter depth and proprietary component repair capabilities while enhancing our presence in USM. We are thrilled to partner with great entrepreneurs like Eddie Montalvo and Sean Beaubien and look forward to working with the rest of their team who have developed a high quality customer-focused MRO business" said Chris Curtis, Chief Executive Officer of Wencor G

Kofax Advances Enterprise-Wide Deployment of Next-Generation Robotic Process Automation to Rapidly and Exponentially Scale the Digital Workforce14.11.2018 14:00Pressemelding

Kofax RPA Powers Industry’s First Single-Vendor Intelligent Automation Offering; Free 12-Month Trial Provides Time to Build, Deploy and Measure Results with No Commitment IRVINE, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Kofax ®, a leading supplier of Intelligent Automation software to automate and digitally transform end-to-end business processes, today announced Kofax RPA’s next-generation robotic process automation (RPA) capabilities that leverage artificial intelligence (AI) and machine learning (ML). Providing “out-of-the-box” functionality, Kofax is first to market with a comprehensive, single-vendor, single-platform, Intelligent Automation solution. “Early adopters of RPA have experienced the many benefits in shifting human labor from ‘data gatherer’ to ‘data user’ roles. Increased productivity helps them remain on track for profitable growth, improved customer service and significant competitive advantage,” said Reynolds C. Bish, Chief Executive Officer of Kofax. “These excepti

Biome Grow subsidiary, Highland Grow, receives license to sell to other licensed producers from Health Canada14.11.2018 14:00Pressemelding

TORONTO, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE:BIO) (Frankfurt:6OTA) is pleased to announce its Nova Scotia-based subsidiary, Highland Grow Inc. (“Highland Grow”), has received its license to sell to other licensed producers from Health Canada in accordance with subsection 11(5) of the Cannabis Regulations. "This license gives the company additional commercial sales avenues and flexibility for our high quality cannabis products and services that are ready for our customers," said Khurram Malik, CEO of Biome. The Health Canada license, issued in accordance with the Cannabis Act and Cannabis Regulations, specifically grants Highland Grow the ability to: possess cannabis; obtain dried cannabis, fresh cannabis, cannabis plants or cannabis plant seeds by cultivating, propagating, and harvesting cannabis; and, to sell cannabis in accordance with subsection 11(5) of the Cannabis Regulations. With this license, Highland Grow is positioned to sell and

Colliers International Expands in South Florida14.11.2018 13:30Pressemelding

Acquisition of Preeminent Brokerage and Management Firm Strengthens Leadership and Service Offering TORONTO and MIAMI, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Leading global commercial real estate services and investment management firm Colliers International Group Inc. (NASDAQ and TSX: CIGI) today announced the acquisition of Continental Real Estate Companies Commercial Properties Corp. (“CREC”), a market-leading commercial real estate services firm specializing in property management, project management and sales and lease brokerage. Founded in 1989 by Warren Weiser and Carol Greenberg Brooks, this acquisition brings an extensive portfolio of more than 12.6 million square feet of office, industrial and retail space in Florida and more than 100 professionals operating from three offices throughout the state to Colliers. Terms of the transaction were not disclosed. “This strategic acquisition positions Colliers as the top management and retail brokerage firm in the vibrant South Florida mark

ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting14.11.2018 13:30Pressemelding

New clinical data highlight potential of novel pyrrolobenzodiazepine-based antibody drug conjugates for the treatment of relapsed or refractory lymphomas LAUSANNE, Switzerland, Nov. 14, 2018 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that data from Phase I clinical trials of ADCT-402 (loncastuximab tesirine) and ADCT-301 (camidanlumab tesirine) have been selected for oral and poster presentations at the 60th American Society of Hematology (ASH) Annual Meeting, which is being held December 1-4 in San Diego. Jay Feingold, MD, PhD, Chief Medical Officer and Senior Vice President of Clinical Development at ADC Therapeutics, said, “We look forward to sharing updated data from our first-in-human clinical trials of ADCT-402 and ADCT-301 in multiple subtypes of lymphoma at the 2018 ASH Annual Meeting. Interim data show that ADCT-402, which targets CD

Major telco company partners with Vricon to accelerate 5G rollouts across the USA14.11.2018 13:00Pressemelding

Vricon supports major U.S. telecommunications firm with high-resolution 3D geodata for urban and suburban regions across the United States McLean, VA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Vricon is pleased to announce that a major U.S. telecommunications company recently acquired Vricon’s high-resolution 3D geodata to support large-scale 5G telecommunications network planning and design. Under the multimillion-dollar contract, Vricon will provide the firm with 3D data of urban and suburban population centers across the United States. The company is leveraging Vricon’s recent innovations in mapping to accelerate 5G infrastructure planning nationwide. 5G increases the need for accurate, high-resolution geodata. Vricon’s unique big-data solution uses the world’s largest archive of 50cm commercial satellite imagery; the solution is built using automated 3D modeling algorithms that create cost-effective, scalable geodata. By adopting Vricon’s unique mapping technology, telecommunications compa

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom